Sinsin Pharmaceutical Co., Ltd

KOSDAQ:A002800 Stock Report

Market Cap: ₩81.9b

Sinsin Pharmaceutical Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Ki Lee Byoung

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureno data
CEO ownership0.3%
Management average tenureno data
Board average tenureno data

Recent management updates

Recent updates

Analysis Article • Apr 08

Sinsin Pharmaceutical (KOSDAQ:002800) Takes On Some Risk With Its Use Of Debt

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Analysis Article • Jul 30

What Sinsin Pharmaceutical Co., Ltd's (KOSDAQ:002800) 40% Share Price Gain Is Not Telling You

The Sinsin Pharmaceutical Co., Ltd ( KOSDAQ:002800 ) share price has done very well over the last month, posting an...
Analysis Article • Mar 20

Sinsin Pharmaceutical's (KOSDAQ:002800) Profits May Not Reveal Underlying Issues

Sinsin Pharmaceutical Co., Ltd's ( KOSDAQ:002800 ) robust recent earnings didn't do much to move the stock. However the...
Analysis Article • Mar 06

What Kind Of Shareholders Hold The Majority In Sinsin Pharmaceutical Co., Ltd's (KOSDAQ:002800) Shares?

A look at the shareholders of Sinsin Pharmaceutical Co., Ltd ( KOSDAQ:002800 ) can tell us which group is most...
Analysis Article • Feb 08

Is Sinsin Pharmaceutical (KOSDAQ:002800) A Risky Investment?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Analysis Article • Jan 18

If You Had Bought Sinsin Pharmaceutical (KOSDAQ:002800) Stock A Year Ago, You Could Pocket A 24% Gain Today

It might be of some concern to shareholders to see the Sinsin Pharmaceutical Co., Ltd ( KOSDAQ:002800 ) share price...
Analysis Article • Dec 25

We're Not Counting On Sinsin Pharmaceutical (KOSDAQ:002800) To Sustain Its Statutory Profitability

Many investors consider it preferable to invest in profitable companies over unprofitable ones, because profitability...
Analysis Article • Nov 29

What Kind Of Investors Own Most Of Sinsin Pharmaceutical Co., Ltd (KOSDAQ:002800)?

Every investor in Sinsin Pharmaceutical Co., Ltd (KOSDAQ:002800) should be aware of the most powerful shareholder...

CEO

Ki Lee Byoung

no data
Tenure

Ki Lee Byoung is President & CEO of Sinsin Pharmaceutical Co., Ltd.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/14 14:23
End of Day Share Price 2026/05/14 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Sinsin Pharmaceutical Co., Ltd is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.